Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Aug 9, 2026, 18:03Mohamed Allaf: Aspirin and Clopidogrel Show Comparable Long-Term Survival After TAVI
-
Aug 9, 2026, 18:00Sangeeta Pathak: Delivering a Talk on Sustainable Blood Systems and Haemovigilance
-
Aug 9, 2026, 15:33Tareq Abadl: Kell System and Anti-K Alloimmunization
-
Aug 9, 2026, 15:16Antonella Cordoba: Emicizumab and the Evolving Landscape of Hemophilia A
-
Aug 9, 2026, 14:53Daniel Pereira Monteiro: Understanding Isoelectric Focusing in Hemoglobin Testing
-
Aug 9, 2026, 14:23Retheesh DasÖ‰ Edema Is a Sign, Not a Diagnosis
-
Aug 9, 2026, 13:56Binay Shah: Building a Future of Accessible Cancer Care
-
Aug 9, 2026, 13:44Taking Charge of Your Bleeding Disorder – National Bleeding Disorders Foundation
-
Aug 9, 2026, 13:17Andrew Zapfel: Building a Stronger Future for Sickle Cell Care in Kenya